News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

QR Pharma’s Posiphen Was Shown in a Clinical Mechanism of Action Study to Enter the Brain and to Inhibit Amyloid Precursor Protein


7/14/2010 10:27:32 AM

RADNOR, Pa.--(BUSINESS WIRE)--QR Pharma, Inc., a developer of novel drugs to treat Alzheimer’s disease (AD), is presenting a poster today on positive clinical data from its recent mechanism of action study in mild cognitive impaired (MCI) patients at the International Congress on Alzheimer’s Disease (ICAD 2010).

Read at BioSpace.com

comments powered by Disqus
QR Pharma
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES